



TR
1639

I hereby certify that the correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on July 19, 2005.

COMMUNICATION
Examining Group 1639
Patent Application
Docket No. TPI-T600XC1
Serial No. 09/994,585

Frank C Eisenschenk

Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Jon D. Epperson
Art Unit : 1639
Applicant : Douglas Levinson
Serial No. : 09/994,585
Filed : November 27, 2001
Conf. No. : 7294
For : Rapid Identification of Conditions, Compounds, or Compositions That Inhibit, Prevent, Induce, Modify, or Reverse Transitions of Physical State

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

COMMUNICATION


Sir:

On November 27, 2001 Applicant submitted an Information Disclosure Statement to be considered and made of record in the above-referenced patent application. Pursuant to a request from the Examiner in the Office Action dated April 4, 2005, Applicant is providing a PTO/SB/08 form in order to provide missing page and/or date information for certain references listed in the PTO-SB008-1449 submitted with the November 27, 2001 Information Disclosure Statement in accordance with Examiner's suggestion. Copies of the references listed are not provided with this Communication as they were provided with the Information Disclosure Statement of November 27, 2001. Applicant respectfully asserts that no new material has been added to the PTO/SB/08 form beyond that which was provided on November 27, 2001, other than the missing page and/or date information. Applicant respectfully requests that the Examiner consider the

references listed on the Form PTO/SB/08 and make their consideration of record in the subject application.

Applicant believes that no fees are due in connection with filing this Communication. However, the Commissioner is hereby authorized to charge any fees under 37 CFR 1.16 or 1.17 as required by this paper to Deposit Account 19-0065.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Attachment: Form PTO/SB/08 (1 page)



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|------------------------------------------------------------------------------------------------------------------------------------|---|--------------------------|-------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 09/994,585 |
| | | Filing Date | November 27, 2001 |
| | | First Named Inventor | Douglas Levinson |
| | | Group Art Unit | 1639 |
| | | Examiner Name | Jon D. Epperson |
| | | Attorney Docket Number | TPI-T600XC1 |
| Sheet | 1 | of | 2 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | R1 | Craw, S. <i>et al.</i> "Case-based design for tablet formulation" XP-000934085, Zeneca Pharmaceuticals, UK pages. 358-369, 1998. (previously reference LD) | |
| | R2 | Ferwerda, R. <i>et al.</i> "The use of FT-Raman spectroscopy and chemometric procedures in the analysis of polymers" Nicolet Instrument Corporation, Application Note AN97100, pp. 1-2, 1997. (previously reference QD) | |
| | R3 | Fodor, S.P. <i>et al.</i> "Light-directed, spatially addressable parallel chemical synthesis" <i>Science</i> 251(499):767-773, 1991. (previously reference TD) | |
| | R4 | Petty, C. <i>et al.</i> "Applications of FT-Raman spectroscopy in the pharmaceutical industry", Nicolet Instruments Pamphlet. (previously references ZE), 11(5):41-45, 1996. | |
| | R5 | Petty, C. <i>et al.</i> "The use of FT-Raman spectroscopy in the study of formulated pharmaceuticals" Nicolet Instruments Application Note AN9262, pp. 1-4, 1995. (previously reference AF) | |
| | R6 | Shah, K. <i>et al.</i> "Automated analytical systems for drug development studies, II. A system for dissolution testing" <i>J. Pharm. & Biomed. Anal.</i> 12(12):1519-1527, 1994. (previously reference FF) | |
| | R8 | | |
| | R9 | | |
| | R10 | | |
| | R11 | | |
| | R12 | | |
| | R13 | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.